Cyclophosphamide hydrate

Research use only, not for human use.

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities; used to treat cancers and autoimmune diseases.

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities; used to treat cancers and autoimmune diseases.Chemotherapeutic Agents Approved(In Vitro):Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide. Cyclophosphamide inhibits the AChE reversibly with an IC50 of 511 μM. Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture.(In Vivo):Cyclophosphamide (injected i.p.;2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.

Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide.Cyclophosphamide inhibits the AChE reversibly with an IC50 of 511 μM.Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture.

Cyclophosphamide (injected i.p.;2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors. Animal Model:Six to eight-week old female C3H/HeN mice bearing SW1 tumors Dosage:2 mg/mouse Administration:Injected i.p.; 2mg/mouse in 0.1 mL PBS; Four days Result:Increased the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.

Cyclophosphamide monohydrate

Cell Cycle/DNA Damage

DNA Alkylator

DNA|MRP1

Cancer

Chemotherapeutic

6055-19-2

279.1012

C7H17Cl2N2O3P

>98% (HPLC)

DMSO: ≥ 38 mg/mL

O.ClCCN(CCCl)P1(=O)NCCCO1

2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, hydrate (1:1)

(-20℃)

With Ice Pack

≥ 2 years